PG545 Preclinical Anti-Cancer Activity Presented at the AACR Annual Meeting - PharmaLive.com (press release)

PG545 Preclinical Anti-Cancer Activity Presented at the AACR Annual Meeting - PharmaLive.com (press release): "

PG545 Preclinical Anti-Cancer Activity Presented at the AACR Annual Meeting PharmaLive.com (press release) Brisbane, Australia, 5th April 2011 - Progen Pharmaceuticals Ltd (ASX:PGL,OTC:PGLA) announced today that it had presented new preclinical data on its dual angiogenesis and heparanase inhibitor, PG545, at the American Association for Cancer Research ... and more »

"